Skip to content

Aspirin in Moyamoya Disease

The Clinical Benefit and Risk of Oral Aspirin for Moyamoya Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020377
Enrollment
Unknown
Registered
2018-12-27
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moyamoya disease

Interventions

Case series:Aspirin

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. has been diagnosed with moaymoya disease (using the MRA/DSA); 2. signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. has aneurysm, AVM, intracranial tumor, hydrocephalus or intracranial hemorrhage; 2. allergic to contrast medium.

Design outcomes

Primary

MeasureTime frame
Percentage of patients with the 2-year new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage) [ Time Frame: at 7days, 1months,3 months, 6 months, 12 months, 18 months, 24 months or end of trial];

Secondary

MeasureTime frame
Percentage of patients with the 2-year new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually. [ Time Frame:at 7days, 1months,3 months, 6 months, 12 months, 18 months, 24 months or end of trial ];Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 2 year follow-up [ Time Frame: at 7days, 1months,3 months, 6 months, 12 months, 18 months, 24 months or end of trial ];

Countries

China

Contacts

Public ContactJizong Zhao

Beijing Tiantan Hospital, Capital Medical University

zhaojz205@163.com+86 010-59976523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026